Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May;28(5):1100-11.
doi: 10.1007/s11095-011-0369-x. Epub 2011 Feb 8.

Development of a bayesian forecasting method for warfarin dose individualization

Affiliations

Development of a bayesian forecasting method for warfarin dose individualization

Daniel F B Wright et al. Pharm Res. 2011 May.

Abstract

Purpose: The aim of this study was to develop a Bayesian dose individualization tool for warfarin. This was incorporated into the freely available software TCIWorks ( www.tciworks.info ) for use in the clinic.

Methods: All pharmacokinetic and pharmacodynamic (PKPD) models for warfarin in the medical literature were identified and evaluated against two warfarin datasets. The model with the best external validity was used to develop an optimal design for Bayesian parameter control. The performance of this design was evaluated using simulation-estimation techniques. Finally, the model was implemented in TCIWorks.

Results: A recently published warfarin KPD model was found to provide the best fit for the two external datasets. Optimal sampling days within the first 14 days of therapy were found to be days 3, 4, 5, 11, 12, 13 and 14. Simulations and parameter estimations suggested that the design will provide stable estimates of warfarin clearance and EC50. A single patient example showed the potential clinical utility of the method in TCIWorks.

Conclusions: A Bayesian dose individualization tool for warfarin was developed. Future research to assess the predictive performance of the tool in warfarin patients is required.

PubMed Disclaimer

References

    1. Am J Geriatr Pharmacother. 2007 Sep;5(3):232-5 - PubMed
    1. Br J Pharmacol. 2008 Aug;154(8):1691-700 - PubMed
    1. Clin Pharmacol Ther. 1978 Feb;23(2):212-7 - PubMed
    1. Clin Pharmacol Ther. 1969 Jan-Feb;10(1):22-35 - PubMed
    1. Lancet. 1996 Sep 7;348(9028):633-8 - PubMed

LinkOut - more resources